key: cord-0265652-kvmfx383 authors: Rottenstreich, A.; Zarbiv, G.; Oiknine-Djian, E.; Vorontsov, O.; Zigron, R.; Kleinstern, G.; Wolf, D.; Porat, S. title: Early versus late third trimester maternal SARS-CoV-2 BNT162b2 mRNA immunization maximizes transplacental antibody transfer and neonatal neutralizing antibody levels date: 2021-09-02 journal: nan DOI: 10.1101/2021.08.30.21262875 sha: 358e3372867dc6240527310255907c64978fde55 doc_id: 265652 cord_uid: kvmfx383 Objective We aimed to assess the impact of early versus late third trimester maternal SARS-CoV-2 vaccination on transplacental transfer and neonatal levels of SARS-CoV-2 antibodies. Methods Maternal and cord blood sera were collected following term delivery after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination, with the first vaccine dose administered during 27-36 weeks gestation. SARS-CoV-2 spike protein (S) and receptor binding domain (RBD)-specific, IgG levels and neutralizing potency were evaluated in maternal and cord blood samples. Results The study cohort consisted of 171 parturients (median age, 31 years; median gestational age, 39.7 weeks): 83 (48.5%) immunized at early 3rd trimester (1st dose at 27-31 weeks), and 88 (51.5%) immunized at late 3rd trimester (1st dose at 32-36 weeks). All mother-infant paired sera were positive for anti S- and anti-RBD-specific IgG. Anti-RBD-specific IgG concentrations in neonatal sera were higher following early versus late 3rd trimester vaccination and were positively correlated with increasing time since vaccination (r= 0.26; P=0.001). The median placental transfer ratios of anti-S and anti-RBD specific IgG were increased following early versus late 3rd trimester immunization (anti-S ratio:1.3 vs. 0.9, anti-RBD-specific ratio:2.3 vs. 0.7, P<0.001). Neutralizing antibodies placental transfer ratio was greater following early versus late 3rd trimester immunization (1.9 vs. 0.8, P<0.001), and was positively associated with longer duration from vaccination (r= 0.77; P<0.001). Conclusions Early- as compared to late third trimester maternal SARS-CoV-2 immunization enhanced transplacental antibody transfer and increased neonatal neutralizing antibody levels. Our findings highlight that vaccination of pregnant women early in the third trimester may optimize neonatal seroprotection. On March 2020, Coronavirus Disease 19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization [1] . Up to May 2021, the pandemic has afflicted over 152 million individuals resulting in over 3 million deaths. Global efforts to combat COVID-19 have led to the development of numerous vaccines including two novel mRNA-based vaccines, which were shown to be highly effective in preventing SARS-CoV-2-related illness [2] [3] [4] . In Israel, a nationwide mass vaccination campaign against COVID-19 using the BNT162b2 (Pfizer/BioNTech) mRNA vaccine has commenced in December 2020. Pregnant women and their infants, particularly neonates, are at a higher risk for severe SARS-CoV-2 infection. Pregnant women who contract COVID-19 are more likely to be admitted to intensive care unit and require invasive ventilation due to COVID-19 compared to nonpregnant women [5] [6] [7] [8] . Furthermore, maternal SARS-CoV-2 infection has been associated with adverse perinatal outcomes including preterm delivery and stillbirth [5] [6] [7] [8] . While children have been shown to be more mildly affected by COVID-19 compared with adults, infants are at significantly higher risk for severe disease course as compared to older children [9, 10] . The two SARS-CoV-2 mRNA vaccines of Pfizer and Moderna were shown to elicit a robust immune response among pregnant women [11] , coupled with data supporting their safety throughout gestation [12] . In addition to their suggested role in preventing maternal illness, recent studies have demonstrated that antenatal vaccination may lead to transplacental transfer of maternally-derived anti-SARS-CoV-2 antibodies [11, [13] [14] [15] . As children, including young infants, are currently not eligible for SARS-CoV-2 vaccination, offering neonatal seroprotection in the early, vulnerable stages of life through maternal immunization is of paramount importance. This principle is well-established for the prevention of other All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint potentially life-threatening respiratory infections such pertussis and influenza [16] [17] [18] [19] [20] . Defining the optimal timing for maternal SARS-CoV-2 immunization is crucial to maximize maternofetal antibody transfer and infant protection. Given the high clinical relevance, we aimed to determine the impact of maternal SARS-CoV-2 immunization timing on the efficacy of transplacental antibody transfer. A prospective study following women admitted for delivery was performed during February-April 2021 at Hadassah Medical Center, a tertiary-care university affiliated hospital in Jerusalem, Israel with over 10,000 deliveries annually. Women who received the SARS-CoV-2 BNT162b2 mRNA vaccine during pregnancy were eligible for this study. The final study cohort included those who received the first vaccine dose at 27-36 weeks gestation. Parturients who delivered prematurely (<37 weeks gestation), multifetal gestations, and those who did not complete the two-dose vaccine series prior to delivery, were excluded. Demographic and clinical data, were collected at the time of enrollment. The institutional review board of the Hadassah Medical Center approved this study (HMO-0064-21). Maternal and cord blood sera were collected following delivery after obtaining written informed consent. Spike protein (S) (Liaison SARS-CoV-2 S1/S2 IgG, DiaSorin, Saluggia, Italy) and receptor binding domain (RBD)-specific (Architect SARS-CoV-2 IgG II Quant assay, Abbott Diagnostics, Chicago, USA), IgG levels were evaluated in maternal and cord blood sera. Maternal and cord blood sera were also tested for SARS-CoV-2 RBD IgM (Liaison, DiaSorin, Saluggia, Italy). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint For a subset of mother/newborn dyads, neutralizing antibody titers against SARS-CoV-2 were defined using a wild-type SARS-CoV-2 virus microneutralization assay as previously described [21] , with minor modifications. Briefly, serial two fold dilutions of heat inactivated serum samples (starting from 1:10; diluted in DMEM in a total volume of 50 μ l) were incubated with an equal volume of viral solution, containing 100 tissue culture infectious dose (TCID50) of SARS-CoV-2 isolate USA-WA1/2020 (NR-52281; obtained from BEI resources), for 1 hour in a 96-well plate (at 37°C in humidified atmosphere with 5% CO 2 ). The serum-virus mixtures (100 µL; 8 replicates of each serum dilution) were then added to a 96-well plate containing a semi confluent VERO E6 cell monolayer (ATCC CRL-1586; maintained as described [22] ). Following 3 days of incubation (at 37°C in a humidified atmosphere with 5% CO 2 ), the cells in each well were scored for viral cytopathic effect (CPE). The neutralization titer (NT 50 ) was defined as the reciprocal of the highest serum dilution that protected 50% of culture wells from CPE. Positive and negative serum controls, cell control, and a viral back-titration control were included in each assay. [16] . Correlations were reported using the Pearson's test with the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint correspondent R and P values. In addition, a multivariable linear regression analysis was performed to assess factors independently associated with neonatal antibody levels. The data were analyzed using Software Package for Statistics and Simulation (IBM SPSS version 24, IBM Corp, Armonk, NY). During the study period, samples were collected from 207 parturients who received the SARS-CoV-2 BNT162b2 mRNA throughout gestation and agreed to participate. Of them, 36 SARS-CoV-2 IgM antibodies were not detected in any of the neonates, and were detected in 30 (17.5%) parturients, all of whom were vaccinated late in the 3 rd trimester. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint β =0.83; P<0.001, respectively), with no association found with all other maternal, pregnancy and delivery characteristics (see Table S1 for the analyzed characteristic). Neutralizing SARS-CoV-2 antibodies were assessed in 33 maternal-infant pairs following early 3 rd trimester vaccination (n=14) and late 3 rd trimester vaccination (n=19). Neonatal sera neutralizing activity (as reflected by NT 50 values) was positively correlated to maternal sera neutralizing activity (r= 0.43; P=0.01; Figure 5A ) and neonatal anti-RBD concentrations (r= 0.68; P<0.001; Figure 5B ). Placental transfer ratio of neutralizing SARS-CoV-2 antibodies was significantly higher following early 3 rd trimester immunization as compared to late 3 rd trimester immunization (median 1.9 vs. 0.8, P<0.001) ( Figure 5C ), and was positively associated with increasing time from vaccination (r= 0.77; P<0.001; Figure 5D ) and anti-RBD placental transfer ratio (r= 0.82; P<0.001; Figure 5E ). Neutralizing antibodies placental transfer ratio was above 1 in all 14 (100.0%) mother-neonates dyads vaccinated early in the 3 rd trimester and in 7 (36.8%) of those vaccinated in late 3 rd trimester (P<0.001). This study investigated the transplacental antibody transfer in 171 mother/newborn dyads, following antenatal SARS-CoV-2 BNT162b2 mRNA vaccination. Early-compared to late third trimester maternal immunization was associated with higher neonatal anti-SARS-CoV-2 antibody levels and serum neutralizing activity. The current study findings may support the role of vaccination early at the third trimester to optimize maternofetal antibody transfer and neonatal seroprotection. Pregnant women were excluded from the initial trials evaluating the different SARS-CoV-2 vaccines [2, 3] . Nevertheless, while universal recommendations have not yet emerged, given the risk for severe disease course and the accumulating reassuring data for their utilization in the setting of pregnancy [11, 12] , the world Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and other agencies advocate offering pregnant All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint women to receive the SARS-CoV-2 vaccine following shared decision making [23] [24] [25] [26] . The far-reaching potential to confer neonatal protection against COVID-19 via maternal immunization raises critical questions concerning the optimal timing of antenatal vaccination. Physiologically, transplacental antibody transfer is a dynamic process starting in the second trimester, however, it is most predominant in the third trimester [27, 28] . While for maternal pertussis and influenza vaccination this issue has been extensively studied [16] [17] [18] [19] [20] , as most women have been previously exposed or immunized against these pathogens, the findings may not apply for the different SARS-CoV-2 vaccines, which prime a de-novo immune response. In this study, we evaluated pregnant women immunized with the SARS-CoV-2 BNT162b2 mRNA vaccine, with the first dose given between 27-36 weeks gestation. We demonstrated that maternal immunization during the early third trimester (27- following early third trimester vaccination [16] [17] [18] [19] [20] . While encouraging, future studies should All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. The major strength of our study is its relatively large cohort size, which allowed for a robust analysis of the superiority of early third trimester immunization. Nevertheless, this study has several caveats. First, the observational single-center design of the study may limit the generalizability of our findings. Second, the effects of maternal immunization in early pregnancy as well as of the impact of other SARS-CoV-2 vaccines on transplacental antibody transfer dynamics remain to be determined. The former could provide maternal protection against COVID-19 through the longer course of pregnancy and may benefit preterm infants. Finally, vaccine-induced maternally-derived antibodies might blunt the infant humoral immune response to future vaccination; while the clinical significance of this interference effect is largely unknown [28] , it should be acknowledged and further explored. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The current study results indicate that early third trimester immunization has the potential to maximize maternofetal transplacental antibody transfer thereby affording adequate seroprotection during early infancy. As the strategy of maternal SARS-CoV-2 immunization is gaining support, there is a critical need for further scientific evidence to inform the ideal timing for vaccination during pregnancy that would provide mothers and neonates with the highest clinical protection against COVID-19. As the extent of SARS-CoV-2 community spread declines in several parts of the globe, optimizing neonatal immunity may be more heavily weighted by immunization policy makers. Dr Rottenstreich and Prof. Wolf had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Porat, Rottenstreich, Wolf. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Rottenstreich, Zarbiv, Porat, Kleinstern, Oiknine-Djian, Wolf. Laboratory analyses: Oiknine-Djian, Vorontsov, Wolf. Statistical analysis: Rottenstreich, Kleinstern. All authors read and approved the final manuscript. We thank Dr. Doron Kabiri, Dr. Shlomi Yahalomi, Prof. Yosef Ezra and Dr. Roy Alter for their assistance in patients' enrollment. We also thank Rimma Barsuk and Yulia Yachnin for their technical assistance. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Maternal and neonatal characteristics among SARS-CoV-2 BNT162b2 immunized pregnant women in relation to vaccination timing (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint specific (F) IgG in relation to maternal third trimester immunization timing. Horizontal line represents the median. Anti-RBD-specific (A) IgG neonatal concentrations and placental transfer ratio (B) in relation to gestational age at the time of vaccination All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint Did not receive second dose. n=1 Twin gestation. n=1 World Health Organization. WHO Director-General's opening remarks at the Mission briefing on COVID-19 -12 Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARSCoV-2 vaccine BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy: SET-NET, 16 jurisdictions COVID-NET Surveillance Team. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19-COVID-NET, 14 states COVID-19 vaccine response in pregnant and lactating women: a cohort study Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons Efficient maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood Association between third-trimester Tdap immunization and neonatal pertussis antibody concentration Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis Immunization of pregnant women against pertussis: the effect of timing on antibody avidity The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone Human nasal and lung tissues infected ex vivo with SARS-CoV-2 provide insights into differential tissue-specific and virus-specific innate immune responses in the upper and lower respiratory tract COVID-19 (coronavirus disease): people with certain medical conditions The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations The American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19 Society for Maternal-Fetal Medicine (SMFM) Statement: SARS-Co-V-2 Vaccination in pregnancy Maternal immunization: optimizing protection for the mother and infant Vaccination during pregnancy: current and possible future recommendations Compromised SARS-CoV-2-specific placental antibody transfer Sexually dimorphic placental responses to maternal SARS-CoV-2 infection. bioRxiv. 2021.03.29.437516. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The authors declare that they have no conflicts of interest. Individual-level data will not be made publicly available with this Article. Requests for sharing of deidentified individual-level participant data for scientific research can be directed to the corresponding author. All proposals will be subject to scientific review and institutional review board approval at Hadassah Medical Center. No external funding was used for this study.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted September 2, 2021. ; https://doi.org/10.1101/2021.08.30.21262875 doi: medRxiv preprint